Drug intelligence / Profile preview

ASP6858

Development stage: Phase 1
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASP6858 is an investigational small molecule drug developed for the treatment of chronic kidney disease. It has been evaluated in first-in-human clinical studies, including single and multiple ascending dose trials in healthy subjects to assess its safety, tolerability, and pharmacokinetics[1][2][3]. The compound is being developed by Astellas Pharma. Its precise mechanism of action has not been publicly disclosed.

Beyond the preview

Go deeper on ASP6858.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP6858.

Explore the full profile